Real-world outcome of crizotinib in ROS1-rearranged non-small cell lung cancer patients
Not Applicable
Recruiting
- Conditions
- Neoplasms
- Registration Number
- KCT0005014
- Lead Sponsor
- Asan Medical Center
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 30
Inclusion Criteria
1. Patients who were diagnosed as locally advanced or metastatic NSCLC by histologic or cytologic confirmation
2. Patients who were diagnosed as histologically or cytologically ROS1 positive adenocarcinoma
3. Patients who are to initiate crizotinib treatment for NSCLC
But patients who are already under treatment with crizotinib for ROS1-rearranged adenocarcinoma is eligible to the study
4. Male or female adult patients aged 19 years old and above
5. The patients who provide written informed consent for the study
Exclusion Criteria
1. Patients who have already been treated with cirzotinib(ALK inhibitor)
2. Patients whose medical records are not available for review
Study & Design
- Study Type
- Interventional Study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Objective response rate (ORR)
- Secondary Outcome Measures
Name Time Method Duration of Response (DR), Disease Control Rates (DCR), Time To Progression (TTP), Progression-free-survival (PFS), overall survival(OS);Intracranial-objective response rate (IC-ORR), Intracranial-Time To Progression (IC-TTP), extracranial-Time To Progression (EC-TTP),;Clinicopathologic characteristics;Diagnostic efficacy of liquid biopsy (cell-free RNA and circulating tumor cell);Response rate of crizotinib by ROS1 fusion partner genes;Safety